Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.
Beth Y. Karlan MD
Advertisement
Articles by Beth Y. Karlan MD
Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer
Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Latest Updated Articles
Phase II AMG 386 and Paclitaxel Combination TrialPublished: April 26th 2011 | Updated:
Dr. Karlan Describes AMG 386 Side EffectsPublished: April 29th 2011 | Updated:
Dr. Karlan Discusses AMG 386 in Recurrent Ovarian CancerPublished: May 5th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5